Pular para o conteúdo
Merck
Todas as fotos(3)

Documentos Principais

SML0223

Sigma-Aldrich

Zoledronic acid monohydrate

≥98% (HPLC)

Sinônimo(s):

P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate, Zoledronate monohydrate, [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C5H10N2O7P2·H2O
Número CAS:
Peso molecular:
290.10
Número MDL:
Código UNSPSC:
12352204
ID de substância PubChem:
NACRES:
NA.77

Ensaio

≥98% (HPLC)

Formulário

powder

condição de armazenamento

desiccated
protect from light

cor

white to beige

solubilidade

H2O: ≥2 mg/mL

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O.OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2

chave InChI

FUXFIVRTGHOMSO-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Zoledronic acid monohydrate has been used:
  • as an inhibitor for cell proliferation in glioblastoma, breast cancer tumor and prostate cancer cell line LAPC4
  • as a conjugate with D,L-lactide 75: glycolide 25 (PLGA) to analyze its bone formation functionality in distal femur
  • as an inhibitor for farnesyl diphosphate synthase enzyme in glioblastoma cells

Ações bioquímicas/fisiológicas

Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.
Zoledronic acid (zoledronate) is a bone resorption inhibitor, an inhibitor of farnesyl diphosphate synthase

Nota de preparo

This product is extremely unstable in solution and should be used shortly after reconstitution. If storage of the solution is necessary it can be held at 2-8ºC for no more than 24 hours.

Pictogramas

Exclamation mark

Palavra indicadora

Warning

Frases de perigo

Classificações de perigo

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Órgãos-alvo

Respiratory system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 4

1 of 4

Xu Li et al.
International journal of pharmaceutics, 526(1-2), 69-76 (2017-04-30)
Bisphosphonates are used to treat bone diseases such as osteoporosis and cancer-induced bone pain and fractures. It is thought that modifying the pharmacokinetics and biodistribution profiles of bisphosphonates (i.e. rapid renal clearance and extensive bone absorption) will not only reduce
Xu Li et al.
ACS applied materials & interfaces, 11(7), 7311-7319 (2019-01-29)
Bisphosphonates are generally used to treat bone diseases, such as bone metastasis from cancer. There is evidence that, through the modification of the pharmacokinetics and biodistribution of bisphosphonates by formulating them into nanoparticles, they may be able to treat extraskeletal
Kiichi Yamamoto et al.
Parasitology international, 66(2), 89-99 (2016-12-07)
Recent evidence suggests that 1α,25-dihydroxyvitamin D3 (calcitriol, VD3), the active form of vitamin D (VD), can inhibit the proliferation of microorganisms. In the present study, we conducted in vitro experiments and utilized in vivo murine models to investigate the antimalarial
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Akoury E, et al.
Cancer Cell International, 19(1), 28-28 (2019)
Controlled delivery of zoledronate improved bone formation locally in vivo
Gou W, et al.
PLoS ONE, 9(3), e91317-e91317 (2014)

Conteúdo relacionado

Discover Bioactive Small Molecules for Lipid Signaling Research

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica